Physician

Adam D Dratch, MD

According to 2025 Medicare claims, Adam Dratch, MD (NPI: 1891798096) practices nephrology in the Allentown-Bethlehem-Easton, PA-NJ market, with the plurality of this provider's patient population coming from Lehigh, PA. This provider's primary affiliated billing organization is ST. LUKE'S PHYSICIAN GROUP, INC. (NPI: 1588970248; TIN: 232380812) and primary practice location at 18104-5656. Dratch is affiliated with the St. Luke's Medicare ACO (ACO ID: A3560), participating under the MSSP model.

Dratch's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 625 traditional Medicare patients, billed 1,614 HCPCS/CPT codes, and received $124,914 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 996 prescription claims across 169 beneficiaries totaling $51,492 in drug costs, led by Potassium Citrate Er (Potassium Citrate). DME data shows 326 claims. Open Payments data shows 6 records totaling $175. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $162,398 to $51,492. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	686	2,237	$169,471
2016	736	2,134	$184,973
2017	692	1,998	$176,766
2018	757	2,269	$188,244
2019	736	2,179	$172,178
2020	697	1,937	$166,395
2021	665	1,971	$154,984
2022	638	1,839	$138,592
2023	602	1,553	$117,610
2024	625	1,614	$124,914

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	167	1,547	$162,398
2016	179	1,553	$233,157
2017	185	1,870	$375,875
2018	178	1,491	$142,773
2019	172	1,160	$106,240
2020	162	1,068	$139,557
2021	159	1,008	$72,574
2022	173	1,107	$74,476
2023	170	1,009	$108,626
2024	169	996	$51,492

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	161	$12,581
2016	N/R	174	$7,672
2017	N/R	292	$16,252
2018	N/R	288	$14,941
2019	N/R	339	$13,533
2020	N/R	293	$10,060
2021	N/R	198	$3,926
2022	N/R	177	$2,739
2023	N/R	154	$3,166
2024	N/R	326	$7,992

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	63	64	$140
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	56	56	$103
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	51	51	$102
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	195	283	$88
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	312	710	$63

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Potassium Citrate Er	Potassium Citrate	116	5,890	$12,291
Clonidine	Clonidine	24	1,238	$2,793
Nisoldipine	Nisoldipine	12	360	$1,413
Calcium Acetate	Calcium Acetate	18	966	$1,213
Torsemide	Torsemide	43	1,979	$686

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	52	$3,135
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	77	$1,385
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	88	$1,137
J7502	Cyclosporine, oral, 100 mg	N	N/R	11	$1,076
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	65	$1,060

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$175	Janssen Pharmaceuticals, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam D. Dratch, MD?

Tedicare shows public-source Medicare data for Adam D. Dratch, MD (NPI 1891798096), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam D. Dratch, MD have ACO affiliation data?

Adam D. Dratch, MD is shown with ACO affiliation data for St. Luke's Medicare ACO (MSSP, ACO ID A3560).

What billing organization is linked to Adam D. Dratch, MD?

Adam D. Dratch, MD is linked to ST. LUKE'S PHYSICIAN GROUP, INC. (billing NPI 1588970248) in the available physician profile data.

Does Adam D. Dratch, MD have Open Payments data?

Adam D. Dratch, MD has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.